Physician profile
Andrew Shaw
NPI 1619051539
$111,587.79
in general payments reported to CMS, 2019-2025
18 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 97% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,341 · 2020: $2,000 · 2021: $7,215 · 2022: $20K · 2023: $11K · 2024: $68K · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Honoraria: $28K · Travel and Lodging: $21K · Food and Beverage: $2,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,262.50 |
| Honoraria | $27,600.00 |
| Travel and Lodging | $21,207.38 |
| Food and Beverage | $2,222.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $48,075.92 | 2024-2025 | Impella |
| Trevena, INC. | $12,916.49 | 2022 | |
| Fresenius USA Marketing, INC. | $11,128.93 | 2022-2024 | |
| Edwards Lifesciences Corporation | $8,985.62 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $7,269.80 | 2023-2024 | Ultomiris |
| Astrazeneca Uk Limited | $5,370.00 | 2024-2025 | |
| Chugai Pharmaceutical Co., LTD. | $4,453.40 | 2023-2024 | |
| Astellas Pharma INC | $4,290.00 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $2,970.00 | 2021 | |
| Medela Ag | $1,500.00 | 2022 | |
| Genentech, INC. | $1,210.00 | 2024 | |
| Becton, Dickinson and Company | $1,194.59 | 2024-2025 | |
| Nxstage Medical, INC. | $1,124.03 | 2021-2023 | Nxstage System One |
| Pacira Pharmaceuticals Incorporated | $880.00 | 2024 | Exparel |
| Novartis Pharmaceuticals Corporation | $125.00 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $46.90 | 2022 | |
| Dendreon Pharmaceuticals LLC | $33.52 | 2024 | Provenge |
| Ipsen Biopharmaceuticals, INC | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.